Oxymetazoline

In July 2020, the FDA approved Upneeq for acquired blepharoptosis in adults. After having participated in the clinical trials, I am now finding it has significant clinical utility in my everyday practice — see my previous blog on Upneeq.

With almost every exam these days, it seems like patients hate the dreaded phrase “due to your age.” I usually lighten up the verbiage and refer to it as the “A-G-E syndrome” that all of us encounter daily.

A few years back, our clinical research department was approached by Icon, a clinical research organization running what sounded like an interesting study.

Oxymetazoline hydrochloride 0.1%, a preservative-free eye drop, was well tolerated and produced positive outcomes in the treatment of acquired ptosis, according to a study.

Upneeq 0.1%, a novel treatment for acquired blepharoptosis, has been approved by the FDA, according to a press release.

Vertical Pharmaceuticals, a subsidiary of Osmotica Pharmaceuticals, has submitted a new drug application to the FDA for RVL-1201, its acquired blepharoptosis treatment candidate, according to a press release.